Filing Flows › Foghorn Therapeutics (FHTX) › Q2 2026
Foghorn Therapeutics (FHTX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Foghorn Therapeutics (FHTX) reported revenue of $16.1M for the second quarter 2026 (Q2 2026), +113% from a year earlier and +392% from the quarter before. Operating margin was -54.8%, net loss $7.2M (44.7% of revenue).
Foghorn Therapeutics, Q2 2026: revenue $16.1M (+113% year over year), operating margin -54.8%, net loss $7.2M, operating cash flow −$17.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $16.1M | +392% | +113% |
| Operating profit | −$8.8M | — | — |
| Net earnings | −$7.2M | — | — |
| Operating cash flow | −$17.8M | — | — |
What changed
Revenue was $16.1M in Q2 2026, up 113% year over year and up 392% from the previous quarter.
Operating costs exceeded revenue by $8.8M, an operating margin of -54.8%. Total costs fell 13% while revenue rose 113%. The quarter ended with a net loss of $7.2M, narrower than the previous quarter's $19.9M loss. Non-operating items added $1.6M, -22% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$17.8M. Non-cash charges added back $200K of depreciation and amortization and $2.5M of share-based compensation. Working capital and other items used $13.4M. Capital expenditures of $50K exceeded it, leaving free cash flow of −$17.9M.
Questions
What was Foghorn Therapeutics' revenue in the second quarter 2026?
Foghorn Therapeutics (FHTX) reported revenue of $16.1M for the second quarter 2026 (Q2 2026), +113% from a year earlier and +392% from the quarter before.
Was Foghorn Therapeutics profitable in the second quarter 2026?
Operating loss was $8.8M (-54.8% of revenue) and net loss $7.2M.